sponsored
PatientsVille.com Logo

PatientsVille

Cardioplegia Medical Research Studies

Up-to-date List of Cardioplegia Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Cardioplegia Medical Research Studies

Rank Status Study
1 Recruiting The ABC Trial Does All-Blood Cardioplegia Prevent Blood Transfusion in Cardiac Surgery? A Single Centre Pilot Study
Conditions: Coronary Artery Disease;   Valvular Heart Disease
Interventions: Other: All-blood Cardioplegia;   Procedure: Standard Cardioplegia
Outcome Measures: Blood transfusion;   Intra-op diastolic function;   Mortality;   Duration of Ventilation;   Lentgh of stay ICU;   Length of stay - hospital;   Other blood product administration;   Hgb - arrival ICU;   Hgb - prior to Discharge;   Lowest post op Hgb;   Volume of crystalloid delivered in Cardioplegia;   Fluid balance;   Reoperation rate for bleeding;   Inotrope score;   Low output syndrome;   Troponin;   Infection;   intra-op Ventricular function
2 Unknown  Comparison of the Effects of Crystalloid Cardioplegia and HTK Solution for Postoperative Troponin-I and CK-MB Levels After Pediatric Cardiac Surgery
Condition: Myocardial Injury
Interventions: Drug: HTK solution;   Drug: crystalloid Cardioplegia solution
Outcome Measures: myocardial protective effect of HTK solution;   hemodynamic and respiratory data
3 Recruiting The Sublingual Microcirculatory Alterations in Patients Undergoing Extracorporeal Flow Conditions
Condition: Microcirculatory Alterations
Intervention:
Outcome Measures: functional capillary density;   percentage perfused density
4 Unknown  Insulin Cardioplegia for Poor Left Ventricular Function
Condition: Left Ventricular Dysfunction
Intervention: Drug: Insulin Cardioplegia
Outcome Measures: Low Output Syndrome;   Total Troponin I Release
5 Not yet recruiting Phase III Study Comparing Two Methods of Cardioplegia in Aortic Valve Surgery Custodiol-N Versus Custodiol
Conditions: Aortic Valve Disease;   Coronary Artery Disease (CAD)
Interventions: Drug: Custodiol-N;   Drug: Custodiol
Outcome Measures: peak value for CK-MB;   Catecholamine requirement on SICU
6 Recruiting Custodiol-HTK Solution as a Cardioplegic Agent
Conditions: Coronary Artery Disease;   Myocardial Ischemia;   Coronary Disease;   Heart Diseases;   Valvular Heart Disease
Interventions: Drug: Custodiol HTK;   Drug: Cold Blood Cardioplegia
Outcome Measures: Creatine phosphokinase MB isoenzyme (CK-MB)and troponin-I;   Changes in ejection fraction by TTE;   Cardiac dysrhythmias;   All cause mortality;   Time on Mechanically Assisted Ventilation;   Biochemical Markers - Creatine phosphokinase MB isoenzyme (CK-MB)and troponin;   Duration of Vasopressor / Inotropic Agent;   ICU Length of Stay;   Arterial Blood Gases;   Creatinine Levels;   Myocardial Infarction
7 Unknown  Evaluation of a Local Preconditioning Effect in Patients Undergoing Cardiac Surgery
Conditions: Heart Disease;   Coronary Artery Bypass Graft Surgery;   With or Without Concomitant Valve Surgery;   With Antegrade/Retrograde Cold Blood Cardioplegia
Intervention: Device: PICSO
Outcome Measures: Reduction in enzyme leakage measured by AUC.;   Combined endpoint of major adverse cardiovascular events (MACE) and mortality after 30 days.;   N-terminales pro brain natriuretic peptide (NT-pro BNP) values at 1 day pre-surgery as well as 30d and 6 months post-operative;   Pre-operative (1d) as well as post-operative (6, 12, 24, 48, 72 h, 30d) C-reactive protein (CRP) measurements
8 Recruiting Randomized Study of Organ Care System Cardiac for Preservation of Donated Hearts for Eventual Transplantation
Condition: Heart Failure
Interventions: Device: Organ Care System;   Device: Cold Cardioplegia Solution
Outcome Measures: 30-day patient survival following transplantation with the originally transplanted heart and no mechanical circulatory assist device at day 30;   Incidence of all cardiac graft-related serious adverse events;   Incidence of biopsy proven ISHLT grade 2R or 3R acute rejection on any of the surveillance endomyocardial biopsies or clinically symptomatic rejection requiring augmentation of immunosuppressive therapy during the 30 day follow up;   Length of ICU stay
9 Recruiting Intracoronary Administration of Levosimendan in Cardiac Surgery Patients
Condition: Myocardial Stunning
Interventions: Drug: levosimendan;   Drug: Vitamin B 12
Outcome Measures: change in cardiac output;   EF;   cTnT/CK-MB on the first postoperative morning.
10 Recruiting Effects of Remote Ischemic PreConditioning in Off-pump Versus On-pump Coronary Artery Bypass Grafting(RIPCON)
Condition: Myocardial Injury
Interventions: Procedure: Remote ischemic preconditioning (RIPC);   Procedure: Coronary artery bypass grafting (CABG) without remote ischemic preconditioning protocol;   Procedure: Off-pump Coronary artery bypass surgery without remote ischemic preconditioning
Outcome Measures: Perioperative extent of myocardial injury as measured by cardiac troponin T serum release over 72 hours after coronary bypass surgery and its area under the curve (AUC).;   All-cause mortality;   Major adverse cardiac and cerebrovascular events (MACCE);   Myocardial infarction;   Renal function;   circulating microparticles after coronary bypass surgery
11 Unknown  Intermittent Normoxia Reduces Myocardial Reperfusion Injury
Condition: Hyperoxia
Intervention: Procedure: intermittent normoxia
Outcome Measures: plasma concentration of troponin I;   gene expression of TNFa, IL-6, and IL-10 in myocardium
12 Recruiting Remote Ischemic Preconditioning in Coronary Artery Bypass Grafting With Cold Crystalloid Cardioplegic Arrest
Condition: Myocardial Injury
Interventions: Procedure: RIPC;   Procedure: Control;   Drug: isoflurane+sufentanil anesthesia
Outcome Measures: Perioperative extent of myocardial injury as measured by cardiac troponin I serum release over 72 hours after CABG surgery and its area under the curve (AUC).;   All-cause mortality;   Major adverse cardiac and cerebrovascular events (MACCE);   Myocardial infarction;   Renal function
13 Unknown  Preop Hemodialysis or Intraop Ultrafiltration for Patients With Severe Renal Dysfunction Undergoing Open Heart Surgery
Conditions: Non-Dialysis Dependent Severe Renal Dysfunction;   Cardiovascular Disease
Interventions: Procedure: Open Heart Surgery (OHS);   Procedure: Intraoperative Modified Ultrafiltration (MUF);   Procedure: Hemodialysis (HD)
Outcome Measures: Operative mortality, defined as any death occurring within 30 days after the operation or any death occurring before discharge during the same hospitalization (in percentage).;   Survival at one year after surgery (in percentage).;   Postoperative low cardiac output (in percentage).;   Postoperative permanent neurological deficit (in percentage).;   Postoperative transient neurological deficit (in percentage).;   Postoperative acute renal dysfunction (in percentage).;   Postoperative persistent renal dysfunction requiring hemodialysis (in percentage).;   Postoperative gastrointestinal complication (in percentage).;   Postoperative respiratory failure (in percentage).;   Postoperative systemic infection (in percentage).;   Postoperative local infection (in percentage).;   Postoperative new-onset arrythmia (in percentage).;   Postoperative surgical drainage (in mL).;   Postoperative need for transfusion of blood products (in unit packs).;   Postoperative length of ICU stay (in days);   Postoperative length of hospital stay (in days);   Total hospital costs for the admission of operation (in Euros)
14 Unknown  Comparison of One-stop Hybrid Revascularization Versus Off-pump Coronary Artery Bypass for the Treatment of Multi-vessel Disease
Condition: Coronary Artery Disease
Interventions: Procedure: Minimally invasive direct coronary artery bypass;   Procedure: PCI-Drug eluting stents;   Procedure: Off-pump coronary artery bypass
Outcome Measures: Composite of major adverse cardiac or cerebrovascular events (MACCE) including death, myocardial infarction, stroke and/or repeat revascularization.;   Overall MACCE rate.;   Cardiac death.;   Documented myocardial infarction.;   Target lesion revascularization.;   Recurrence of Angina.;   Cost-effectiveness analysis.;   Quality of life.;   Rehospitalization.
15 Recruiting Comparative Effectiveness of the Minimally Invasive Coronary Artery Bypass Grafting
Conditions: Coronary Artery Disease;   Myocardial Ischemia;   Heart Diseases
Interventions: Procedure: MICS CABG;   Procedure: OPCABG;   Procedure: ONCABG;   Device: Octopus® Nuvo, Starfish® Non-Sternotomy, ThoraTrak®;   Device: Starfish®, Octopus®, Clearview® blower, ClearView® Shunt
Outcome Measures: MACCE;   Procedural success;   Transfusion rate;   Recovery time;   New York Heart Association (NYHA) class modification with respect to baseline;   Wound infection;   New-onset renal failure;   Respiratory insufficiency;   Return to full physical activity postoperatively;   Intensive care unit (ICU) stay
16 Recruiting Ischemic Postconditioning in Cardiac Surgery
Condition: Cardiac Surgery
Intervention: Procedure: Ischemic postconditioning
Outcome Measure: Change in cardiac index between the groups during the first postoperative day
17 Unknown  Comparison of One-stop Hybrid Revascularization Versus Percutaneous Coronary Intervention for the Treatment of Multi-vessel Disease
Condition: Coronary Artery Disease
Interventions: Procedure: Hybrid MIDCAB/PCI;   Procedure: PCI with DES
Outcome Measures: Composite of major adverse cardiac or cerebrovascular events (MACCE) including death, myocardial infarction, stroke and/or repeat revascularization.;   Overall MACCE rate.;   Cardiac death.;   Documented myocardial infarction.;   Target lesion revascularization.;   Recurrence of Angina.;   Cost-effectiveness analysis.;   Quality of life.;   Rehospitalization.;   Stent thrombosis.
18 Unknown  Cardiac Operation Under Totally Endoscope and Cardiopulmonary Bypass (CPB)
Conditions: Congenital Heart Defects;   Heart Valve Diseases
Intervention: Procedure: cardiac operation with totally endoscopic method
Outcome Measures: all cause mortality;   all cause morbidity

These studies may lead to new treatments and are adding insight into Cardioplegia etiology and treatment.

A major focus of Cardioplegia research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Cardioplegia